Literature DB >> 16143572

A new high-performance liquid chromatographic method for determination of warfarin enantiomers.

Abdimajid Osman1, Kerstin Arbring, Tomas L Lindahl.   

Abstract

Warfarin is the most common agent used for control and prevention of venous as well as arterial thromboembolism. Although warfarin is administered as a racemic mixture of two stereoisomers (S and R), the S-form is mainly responsible for the anticoagulant effect. The anticoagulant effect of the drug is monitored by analysis of prothrombin complex (International Normalised Ratio,INR). In some cases, however, the measurements of plasma warfarin concentration are needed. Here, we present a new, rapid, sensitive and cost-effective HPLC-method for the determination of warfarin enantiomers in plasma. The chromatographic system consisted of Waters 616 gradient pump, Waters 996 photo diode array detector, Gilson 230 autoinjector and Pirkle (R,R) Whelk-O1 column (25 cmx4.6 mm I.D., 5 microm). An isocratic mobile phase of methanol/acetonitrile/water (50/10/40, v/v) with 0.1% glacial acetic acid was used. The follow rate was 1 mL/min. Data analysis was carried out with Waters Millennium32. The absorbance at 305 nm was measured with a total run-time of 15 min. Method linearity was studied by establishing regression data containing eight points over the range 0.08-10 microg/mL. In this range, warfarin showed to be linear (r2=0.9997 for S-warfarin and r2=0.9998 for R-warfarin). The limit of detection in plasma was 16 ng/mL for S-warfarin and 18 ng/mL for R-warfarin. Limit of quatitation was defined as 10xLOD. The extraction recovery was approximately 80%. Also the relation between INR and warfarin concentration was investigated. As expected, there was a low correlation between these two variables (r=0.23, y=0.3044x+0.9712). This method offers a rapid and cost-effective determination of warfarin enantiomers in human plasma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16143572     DOI: 10.1016/j.jchromb.2005.08.011

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

1.  Fluorescence Determination of Warfarin Using TGA-capped CdTe Quantum Dots in Human Plasma Samples.

Authors:  A Dehbozorgi; J Tashkhourian; S Zare
Journal:  J Fluoresc       Date:  2015-10-19       Impact factor: 2.217

2.  A chiral HPLC-MS/MS method for simultaneous quantification of warfarin enantiomers and its major hydroxylation metabolites of CYP2C9 and CYP3A4 in human plasma.

Authors:  W Ju; K Peng; S Yang; H Sun; M Sampson; M Z Wang
Journal:  Austin J Anal Pharm Chem       Date:  2014

3.  Development of a chiral micellar electrokinetic chromatography-tandem mass spectrometry assay for simultaneous analysis of warfarin and hydroxywarfarin metabolites: application to the analysis of patients serum samples.

Authors:  Xiaochun Wang; Jingguo Hou; Michael Jann; Yuen Yi Hon; Shahab A Shamsi
Journal:  J Chromatogr A       Date:  2012-11-26       Impact factor: 4.759

4.  Validation and Application of a Simple UHPLC-MS-MS Method for the Enantiospecific Determination of Warfarin in Human Urine.

Authors:  Osama Y Alshogran; Andrew J Ocque; François A Leblond; Vincent Pichette; Thomas D Nolin
Journal:  J Chromatogr Sci       Date:  2015-12-11       Impact factor: 1.618

5.  Separation and determination of warfarin enantiomers in human plasma using a novel polymeric surfactant for micellar electrokinetic chromatography-mass spectrometry.

Authors:  Jingguo Hou; Jie Zheng; Shahab A Shamsi
Journal:  J Chromatogr A       Date:  2007-04-21       Impact factor: 4.759

6.  The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study.

Authors:  Donato Gemmati; Francesco Burini; Anna Talarico; Matteo Fabbri; Cesare Bertocco; Marco Vigliano; Stefano Moratelli; Antonio Cuneo; Maria Luisa Serino; Francesco Maria Avato; Veronica Tisato; Rosa Maria Gaudio
Journal:  PLoS One       Date:  2016-09-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.